Bluesight announces a strategic partnership with GraphiteRx that aims to bring marketplace data, including the catalog of the Mark Cuban Cost Plus Drugs Company, into its CostCheck and ShortageCheck platforms. The integration is expected to expand access to alternative medication suppliers, helping hospitals reduce drug spend and strengthen resilience amid ongoing shortages. Through the partnership, Bluesight users can view Cost Plus Drugs pricing alongside traditional wholesaler options within their existing procurement decision workflows. This added visibility gives pharmacy teams greater flexibility when sourcing medications and making cost-based decisions, addressing the challenges of rising drug costs and persistent shortages.